Daxor (NASDAQ:DXR – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), FiscalAI reports. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $2.80 million.
Daxor Price Performance
DXR opened at $10.08 on Tuesday. The firm has a 50-day simple moving average of $10.38 and a two-hundred day simple moving average of $10.54. Daxor has a 52 week low of $8.56 and a 52 week high of $14.76.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Daxor stock. Osaic Holdings Inc. purchased a new position in Daxor Corporation (NASDAQ:DXR – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned about 0.18% of Daxor as of its most recent filing with the Securities and Exchange Commission (SEC). 1.34% of the stock is currently owned by hedge funds and other institutional investors.
About Daxor
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Recommended Stories
- Five stocks we like better than Daxor
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
